Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: A systematic review and meta-analysis

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2034-2043

  Lim, W Y ^a   Messow, C M ^b   Berry, C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

animal studies; cyclosporin; myocardial infarction; pre clinical; reperfusion injury

Indexed keywords

CYCLOSPORIN; PLACEBO;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL PIG; EXPERIMENTAL RABBIT; EXPERIMENTAL STUDY; FALSE POSITIVE RESULT; HEART; HEART INFARCTION SIZE; HEART PROTECTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; CARDIOTONIC AGENTS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RABBITS; RATS; SPECIES SPECIFICITY; SWINE; TREATMENT OUTCOME;

EID: 84858164801     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01691.x     Document Type: Review

References (47)

1. 2+ induced mitochondrial permeability transition. Cardiovasc Res 61: 115-122. (Pubitemid 38056687)
2. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, (2005a). Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion. J Mol Cell Cardiol 38: 367-374. (Pubitemid 40215206)
3. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize R, (2005b). Post-conditioning inhibits mitochondrial permeability transition. Circulation 111: 194-197. (Pubitemid 40139731)
4. Berry C, Balachandran KP, L'Allier PL, Lespérance J, Bonan R, Oldroyd KG, (2007). Importance of collateral circulation in coronary heart disease. Eur Heart J 28: 278-291.
5. Boengler K, Hilfiker-Kleiner D, (2010). Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischaemia/reperfusion. Basic Res Cardiol 105: 771-785.
6. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, et al,. (2002). The relationship of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following acute myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39: 30-36. (Pubitemid 34059858)
7. Di Lisa F, Canton M, Menabo R, Dodoni G, Bernardi P, (2003). Mitochondria and reperfusion injury: the role of permeability transition. Basic Res Cardiol 98: 235-241. (Pubitemid 36874022)
8. Dow J, Kloner RA, (2007). Post-conditioning does not reduce myocardial infarct size in an in vivo regional ischaemia rodent model. J Cardiovasc Pharmacol Ther 12: 153-163. (Pubitemid 46836328)
9. Dow J, Bhandari A, Kloner RA, (2009). The mechanism by which ischemic postconditioning reduces reperfusion arrhythmias in rats remains elusive. J Cardiovasc Pharmacol Ther 14: 99-103.
10. Duchen MR, McGuinness O, Brown LA, Crompton M, (1993). On the involvement of a cyclosporin A sensitive mitochorndial pore in myocardial reperfusion injury. Cardiovasc Res 27: 1790-1794. (Pubitemid 23337871)
11. Edmundo C, Garcia N, Pavon N, (2007). Inhibition of permeability transition and myocardial reperfusion damage by cyclosporine A. Arch Cardiol Mex 77 (Suppl. 4): s77-s81.
12. Egger M, Davey Smith G, Schneider M, Minder C, (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-624.
13. Fang J, Wu L, Chen L, (2008). Post-conditioning attenuates cardiocyte ultrastructure injury and apoptosis by blocking mitochondrial permeability transition in rats. Acta Cardiol 63: 377-387. (Pubitemid 351929846)
14. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS, (2004). The quantification of infarct size. J Am Coll Cardiol 44: 1533-1542. (Pubitemid 39377707)
15. Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, Scalfaro P, et al,. (2007). Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol 293: H1654-H1661. (Pubitemid 47367212)
16. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M, (2008). Inhibition of GSK3beta by post-conditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768. (Pubitemid 351770456)
17. Gomez L, Li B, Mewton N, Sanchez I, Piot C, Elbaz M, et al,. (2009). Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res 83: 226-233.
18. Griffiths EJ, Halestrap AP, (1993). Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25: 1461-1469. (Pubitemid 24049454)
19. Hausenloy DJ, Yellon DM, (2007). Reperfusion injury salvage kinase signalling: taking RISK for cardioprotection. Heart Fail Rev 12: 217-234. (Pubitemid 350176695)
20. Hausenloy DJ, Yellon DM, (2008). Time to take myocardial reperfusion injury seriously. N Engl J Med 359: 518-520.
21. Hooijmans CR, de Vries R, Leenaars M, Curfs J, Ritskes-Hoitinga M, (2011). Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines. Br J Pharmacol 162: 1259-1260.
22. Huhn R, Hienen A, Weber C, Hollmann MW, Schlack W, Preckel B, (2008). Hyperglycaemia blocks sevoflurane-induced postconditionig in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth 100: 465-471. (Pubitemid 351773615)
23. Ikeda Y, Miura T, Sakamoto J, Miki T, Tanno M, Kobayashi H, et al,. (2006). Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation. Basic Res Cardiol 2006: 418-426. (Pubitemid 44275875)
24. Jiao Z, Gorodnya OM, Yang XM, Fan THM, (2001). Cyclosporine A inhibits cytochrome C release and prevents myocardial cell death induced by ischaemia/reperfusion. J Am Coll Cardiol 37: 346A (Abstract).
25. Karlsson LO, Zhou AX, Larsson E, Astrom-Olsson K, Mansson C, Akyurek LM, et al,. (2010). Cyclosporine does not reduce myocardial infarct size in a porcine ischaemia-reperfusion model. J Cardiovasc Pharmacol Ther 15: 182-189.
26. Karlsson LO, Bergh N, Grip L, (2011). Cyclosporine A, 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion. J Cardiovasc Pharmacol Ther doi: 10.1177/1074248411407636.
27. Kilkenny C, Brown W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. ATP channels. Anesth Analg 101: 1590-1596. (Pubitemid 41720602)
29. Laudi S, Schmitz V, Trump S, Christians U, Steudel W, (2006). Preconditioning with cyclosporine alters survival in murine myocardial ischemia-reperfusion-injury. J Heart Lung Transplant 25: s168; 363 (Abstract 363).
30. Leshnower BG, Sakamoto H, Kanemoto S, Hamamoto H, Zeeshan A, Hinmon R, et al,. (2005). Inhibition of mitochondrial permeability transition produces reperfusion induced myocyte apoptosis and improves early post-MI function. Circulation 112 (Suppl. S): U501-U502. 78th Annual Scientific Session of the AHA.
31. Leshnower BG, Kanemoto S, Matsubara M, Sakamoto H, Hinmon R, Gorman JH, (2008). Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion dependent of calcineurin inhibition. Ann Thorac Surg 86: 1286-1292.
32. Lie RH, Stoettrup N, Sloth E, Hasenkam M, Kroyer R, Nielsen TT, (2010). Post-conditioning with cyclosporine A fails to reduce infarct size in an in vivo porcine model. Acta Anaesthesiol Scand 54: 804-813.
33. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM, (2007). Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 75: 530-535. (Pubitemid 47080966)
34. Macleod MR, Ebrahim S, Roberts I, (2005). Surveying the literature from animal experiments: systematic review and meta-analysis are important contributions. BMJ 331: 110.
35. Macleod MR, Van Der Worp B, Sena ES, Howells DW, Dirnagl U, Donnan GA, (2008). Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 39: 2824-2829.
36. Martindale (1993). The Extra Pharmacopoeia, 30th edn. Pharmaceutical Press: London, p. 467.
37. Massoudy P, Zahler S, Kupatt C, Reder C, Becker BF, Gerlach E, (1997). Cardioprotection by cyclosporine A in experimental ischemia and reperfusion-evidence of nitric oxide dependent mechanism mediated by endothelin. J Mol Cell Cardiol 29: 535-544. (Pubitemid 27192862)
38. Matsubara M, Ranji M, Leshnower BG, Noma M, Ratcliffe SJ, Chance B, et al,. (2010). In vivo fluorometic assessment of cyclosporine on mitochondria function during myocardial ischaemia and reperfusion. Ann Thorac Surg 89: 1532-1537.
39. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
40. Niemann CU, Saeed M, Akbari H, Jacobsen W, Benet LZ, Christians U, et al,. (2002). Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther 302: 1123-1128. (Pubitemid 34920234)
41. Pagel PS, Krolikowski JG, (2009). Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporine A in rabbits. Anesth Analg 108: 1076-1082.
42. Pagel PS, Krolikowski JG, Neff DA, Weihrauch D, Bienengraeber M, Kersten JR, et al,. (2006). Inhibition of glycogen synthase kinase enhances isoflurane induced protection against myocardial infarction during early reperfusion in vivo. Anesth Analg 102: 1348-1354.
43. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al,. (2008). Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Eng J Med 359: 473-481.
44. Skychally A, Schulz R, Heusch G, (2010). Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 24: 85-87.
45. Squadrito F, Altavilla D, Squadrito G, Saitta A, Campo GM, Arlotta GM, (1999). Cyclosporine-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Eur J Pharmacol 364: 159-168. (Pubitemid 29065266)
46. Wang C, Neff DA, Krolikowski JG, Weihrauch D, Bienengraeber M, Warltier DC, et al,. (2006). The influence of B-cell lymphoma 2 protein, an anti-apoptic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic preconditioning in rabbits. Anesth Analg 102: 1355-1360.
47. Xie JR, Yu LN, (2007). Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion. Acta Anaesthesiol Scand 51: 909-913.